Live Earnings Conference Call: Esperion Therapeutics had a scheduled live Q1 2026 earnings call on May 7, 2026 at 7:00AM ET. Get details.

Esperion Therapeutics (ESPR) Financials

$3.14 -0.01 (-0.16%)

As of 02:19 PM Eastern

Compare

Annual Income Statements for Esperion Therapeutics

This table shows Esperion Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-50	-75	-167	-202	-97	-144	-269	-234	-209	-52	-23
Consolidated Net Income / (Loss)	-50	-75	-167	-202	-97	-144	-269	-234	-209	-52	-23
Net Income / (Loss) Continuing Operations	-50	-75	-167	-202	-97	-144	-269	-234	-209	-52	-23
Total Pre-Tax Income	-51	-76	-169	-205	-101	-144	-273	-234	-209	-52	-21
Total Operating Income	-50	-76	-169	-205	-93	-121	-227	-180	-156	54	60
Total Gross Profit	0.00	0.00	0.00	0.00	148	228	78	75	73	264	274
Total Revenue	0.00	0.00	0.00	0.00	148	228	78	75	116	332	403
Operating Revenue	-	-	-	0.00	148	228	78	75	116	332	403
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	43	69	129
Operating Cost of Revenue	-	-	-	-	-	-	-	-	43	69	129
Total Operating Expenses	50	76	169	205	241	349	305	255	229	209	214
Selling, General & Admin Expense	20	18	21	33	66	202	199	136	143	163	166
Research & Development Expense	30	58	148	171	176	147	106	119	86	46	48
Total Other Income / (Expense), net	-0.52	0.00	-0.20	-0.03	-8.12	-23	-46	-54	-54	-106	-81
Interest Expense	0.52	-	0.20	0.03	8.12	23	46	57	59	114	85
Other Income / (Expense), net	-	-	-	-	-	-	-	2.65	5.29	8.02	3.49
Income Tax Expense	-	-	-	-	-	-	-	-	0.00	0.00	1.84
Basic Earnings per Share	($2.26)	($3.33)	($6.98)	($7.54)	($3.59)	($5.23)	($9.31)	($3.52)	($2.03)	($0.28)	($0.11)
Weighted Average Basic Shares Outstanding	22.02M	22.54M	23.93M	26.75M	27.09M	27.47M	28.90M	66.41M	103.11M	187.18M	207.87M
Diluted Earnings per Share	($2.26)	($3.33)	($6.98)	($7.54)	($3.59)	($5.23)	($9.31)	($3.52)	($2.03)	($0.28)	($0.11)
Weighted Average Diluted Shares Outstanding	22.02M	22.54M	23.93M	26.75M	27.09M	27.47M	28.90M	66.41M	103.11M	187.18M	207.87M
Weighted Average Basic & Diluted Shares Outstanding	22.02M	22.54M	23.93M	26.75M	27.09M	27.47M	62.82M	76.57M	185.05M	197.85M	256.81M

This table shows Esperion Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-50	-41	-56	61	-62	-30	-21	-40	-13	-31	62
Consolidated Net Income / (Loss)	-50	-41	-56	61	-62	-30	-21	-40	-13	-31	62
Net Income / (Loss) Continuing Operations	-50	-41	-56	61	-62	-30	-21	-40	-13	-31	62
Total Pre-Tax Income	-52	-43	-53	58	-64	-30	38	-42	-13	-32	66
Total Operating Income	-37	-28	-42	72	2.58	-16	-4.42	-22	7.10	-9.96	85
Total Gross Profit	26	34	-11	138	74	52	69	65	82	87	39
Total Revenue	26	34	32	138	74	52	69	65	82	87	168
Operating Revenue	26	34	32	138	74	52	69	65	82	87	168
Total Cost of Revenue	0.00	0.00	43	0.00	0.00	0.00	-	0.00	0.00	0.00	129
Total Operating Expenses	63	62	31	65	71	68	74	87	75	97	-46
Selling, General & Admin Expense	41	47	14	52	60	57	63	75	68	83	-60
Research & Development Expense	22	15	18	13	11	10	11	13	7.24	14	14
Total Other Income / (Expense), net	-15	-15	-11	-14	-67	-13	42	-19	-20	-22	-19
Interest Expense	15	15	15	14	67	15	-37	19	20	22	23
Basic Earnings per Share	($0.46)	($0.37)	($0.41)	$0.36	($0.33)	($0.15)	($0.16)	($0.21)	($0.06)	($0.16)	$0.32
Weighted Average Basic Shares Outstanding	109.24M	111.87M	103.11M	169.26M	188.79M	194.93M	187.18M	196.13M	197.55M	200.74M	207.87M
Diluted Earnings per Share	($0.46)	($0.37)	($0.41)	$0.34	($0.33)	($0.15)	($0.14)	($0.21)	($0.06)	($0.16)	$0.32
Weighted Average Diluted Shares Outstanding	109.24M	111.87M	103.11M	189.64M	188.79M	194.93M	187.18M	196.13M	197.55M	200.74M	207.87M
Weighted Average Basic & Diluted Shares Outstanding	106.99M	113.72M	185.05M	189.46M	196.22M	197.04M	197.85M	198.20M	201.62M	239.06M	256.81M

This table details how cash moves in and out of Esperion Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-7.70	-39	-3.70	2.51	130	138	-46	-134	-43	63	23
Net Cash From Operating Activities	-38	-48	-131	-149	-70	-85	-264	-175	-135	-24	-13
Net Cash From Continuing Operating Activities	-38	-48	-131	-149	-70	-85	-264	-175	-135	-24	-13
Net Income / (Loss) Continuing Operations	-50	-75	-167	-202	-97	-144	-269	-234	-209	-52	-23
Consolidated Net Income / (Loss)	-50	-75	-167	-202	-97	-144	-269	-234	-209	-52	-23
Depreciation Expense	0.24	0.25	0.26	0.27	0.32	0.55	0.61	0.50	0.16	0.06	0.11
Amortization Expense	0.71	1.01	0.33	-0.22	-0.20	1.64	1.63	1.90	1.29	1.50	3.01
Non-Cash Adjustments To Reconcile Net Income	13	16	19	24	34	60	56	60	59	87	21
Changes in Operating Assets and Liabilities, net	-2.09	10	16	29	-7.30	-4.26	-53	-3.37	14	-61	-15
Net Cash From Investing Activities	-160	10	-36	140	64	21	-50	8.10	43	-0.32	0.00
Net Cash From Continuing Investing Activities	-160	10	-36	140	64	21	-50	8.10	43	-0.32	0.00
Purchase of Property, Plant & Equipment	-0.33	-0.09	-0.02	-0.15	-0.95	-0.87	-	0.00	0.00	-0.32	0.00
Sale and/or Maturity of Investments	121	207	184	166	100	39	0.00	68	43	0.00	0.00
Net Cash From Financing Activities	191	-1.56	163	11	136	202	268	33	50	86	36
Net Cash From Continuing Financing Activities	191	-1.56	163	11	136	202	269	33	50	86	36
Repayment of Debt	-0.64	-1.60	-1.71	-1.05	0.00	-8.41	-0.44	-0.22	0.02	-220	-55
Repurchase of Preferred Equity	-	-	-	-	-	-	-	-	0.00	-344	0.00
Repurchase of Common Equity	-	-	-	0.00	0.00	-55	-	-50	0.00	0.00	-7.50
Issuance of Debt	-	-	-	0.00	124	280	50	0.00	0.00	245	0.00
Issuance of Common Equity	190	0.00	164	-	0.00	0.00	219	91	57	91	88
Other Financing Activities, net	1.18	0.05	1.17	12	12	-15	0.37	-8.02	-6.44	314	10
Cash Interest Paid	-	-	-	-	-	-	-	-	11	11	16
Cash Income Taxes Paid	-	-	-	-	-	-	-	-	0.00	0.00	0.61

This table details how cash moves in and out of Esperion Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	-6.44	-24	-33	144	-37	-45	0.04	-30	-29	6.39	75
Net Cash From Operating Activities	-25	-19	-37	54	-7.21	-35	-35	-23	-31	-4.29	45
Net Cash From Continuing Operating Activities	-25	-19	-37	54	-7.21	-35	-35	-23	-31	-4.29	45
Net Income / (Loss) Continuing Operations	-50	-41	-56	61	-62	-30	-21	-40	-13	-31	62
Consolidated Net Income / (Loss)	-50	-41	-56	61	-62	-30	-21	-40	-13	-31	62
Depreciation Expense	0.05	0.03	0.01	0.00	0.01	0.03	0.03	0.03	0.03	0.03	0.03
Amortization Expense	0.35	0.43	0.43	0.44	0.44	0.45	0.17	0.70	0.82	0.85	0.64
Non-Cash Adjustments To Reconcile Net Income	15	15	15	14	59	6.15	7.48	5.07	6.77	5.21	4.07
Changes in Operating Assets and Liabilities, net	10	6.58	3.96	-22	-5.00	-12	-21	12	-26	21	-21
Net Cash From Financing Activities	0.81	-4.31	4.47	91	-30	-9.10	35	-7.50	2.85	11	30
Net Cash From Continuing Financing Activities	0.81	-4.31	4.47	91	-30	-9.10	35	-7.50	2.85	11	30
Repayment of Debt	-	-	0.02	-	-	-	-200	-	-	-	-55
Issuance of Common Equity	4.31	-0.03	-	91	-	0.53	-0.02	0.00	2.85	11	75
Other Financing Activities, net	-3.50	-4.28	4.45	-0.07	314	-	-9.66	0.00	-	0.14	10

This table presents Esperion Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	296	245	278	143	214	353	382	248	206	344	466
Total Current Assets	214	214	204	143	212	346	329	247	201	338	463
Cash & Equivalents	77	38	34	37	166	305	209	125	82	145	168
Accounts Receivable	-	-	-	-	-	12	23	34	48	80	140
Inventories, net	-	-	-	-	0.00	16	34	35	66	108	146
Prepaid Expenses	2.13	1.99	3.73	6.61	10	12	12	11	4.70	4.74	8.54
Plant, Property, & Equipment, net	0.81	0.67	0.44	0.52	1.15	1.28	0.66	0.16	0.00	0.25	0.34
Total Noncurrent Assets	80	31	73	0.30	1.59	6.09	52	1.09	4.73	5.57	2.98
Goodwill	-	-	-	-	-	-	-	0.06	0.06	0.06	0.06
Other Noncurrent Operating Assets	-	-	-	-	1.53	6.03	52	1.04	4.68	5.51	2.92
Total Liabilities & Shareholders' Equity	296	245	278	143	214	353	382	248	206	344	466
Total Liabilities	8.31	17	33	64	194	449	579	572	661	733	768
Total Current Liabilities	5.63	16	33	64	66	94	73	92	156	246	301
Short-Term Debt	1.60	1.71	1.05	-	-	-	-	-	0.00	55	0.00
Accounts Payable	0.71	4.60	20	45	29	52	18	23	32	52	65
Accrued Expenses	3.31	9.29	12	19	29	32	37	41	63	81	112
Current Deferred Revenue	-	-	-	-	2.15	1.66	5.68	3.51	25	8.52	34
Other Current Liabilities	-	-	-	-	5.69	7.98	13	25	36	50	90
Total Noncurrent Liabilities	2.69	1.02	0.00	0.00	128	355	505	479	505	486	467
Long-Term Debt	2.69	1.02	-	-	0.00	179	258	260	262	238	249
Other Noncurrent Operating Liabilities	-	-	-	-	128	176	246	220	243	249	218
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	287	229	245	79	20	-96	-197	-324	-455	-389	-302
Total Preferred & Common Equity	287	229	245	79	20	-96	-197	-324	-455	-389	-302
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	287	229	245	79	20	-96	-197	-324	-455	-389	-302
Common Stock	442	458	642	678	715	798	964	1,071	1,149	1,267	1,377
Retained Earnings	-154	-229	-396	-598	-695	-839	-1,106	-1,340	-1,549	-1,601	-1,624
Treasury Stock	-	-	-	-	0.00	-55	-55	-55	-55	-55	-55
Accumulated Other Comprehensive Income / (Loss)	-0.48	-0.17	-0.85	-0.32	0.02	0.00	-0.03	-0.00	0.00	0.00	0.00

This table presents Esperion Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	235	221	373	352	314	324	347	364
Total Current Assets	232	218	366	345	308	319	343	360
Cash & Equivalents	138	115	227	189	145	115	86	92
Accounts Receivable	41	43	55	60	68	81	108	119
Inventories, net	46	51	73	84	80	118	139	142
Prepaid Expenses	7.18	9.34	11	11	15	5.32	9.55	7.20
Plant, Property, & Equipment, net	0.03	0.01	0.27	0.31	0.28	0.23	0.20	0.18
Total Noncurrent Assets	2.47	3.07	7.19	6.90	6.28	5.02	4.29	3.38
Goodwill	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
Other Noncurrent Operating Assets	2.41	3.02	7.13	6.85	6.22	4.97	4.23	3.33
Total Liabilities & Shareholders' Equity	235	221	373	352	314	324	347	364
Total Liabilities	607	631	667	697	684	750	781	815
Total Current Liabilities	107	138	165	175	166	271	299	359
Short-Term Debt	-	-	-	-	-	55	55	55
Accounts Payable	25	26	28	48	35	72	75	78
Accrued Expenses	44	54	61	72	75	80	78	99
Current Deferred Revenue	16	20	29	21	15	4.54	22	31
Other Current Liabilities	23	38	46	35	41	60	69	97
Total Noncurrent Liabilities	499	494	503	521	518	479	482	456
Long-Term Debt	261	261	262	262	263	238	243	249
Other Noncurrent Operating Liabilities	239	232	241	259	256	241	238	208
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-372	-410	-294	-344	-370	-426	-434	-451
Total Preferred & Common Equity	-372	-410	-294	-344	-370	-426	-434	-451
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-372	-410	-294	-344	-370	-426	-434	-451
Common Stock	1,135	1,138	1,249	1,261	1,265	1,270	1,276	1,289
Retained Earnings	-1,452	-1,493	-1,488	-1,550	-1,580	-1,641	-1,654	-1,686
Treasury Stock	-55	-55	-55	-55	-55	-55	-55	-55

This table displays calculated financial ratios and metrics derived from Esperion Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	22,518,907.00	22,553,851.00	26,197,749.00	26,811,002.00	27,327,409.00	27,876,626.00	29,077,357.00	73,683,572.00	113,717,785.00	-	239,063,437.00
DEI Adjusted Shares Outstanding	22,518,907.00	22,553,851.00	26,197,749.00	26,811,002.00	27,327,409.00	27,876,626.00	29,077,357.00	73,683,572.00	113,717,785.00	-	239,063,437.00
DEI Earnings Per Adjusted Shares Outstanding	-2.21	-3.32	-6.37	-7.53	-3.56	-5.15	-9.25	-3.17	-1.84	-	-0.09
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-35	-53	-118	-143	-65	-85	-159	-126	-109	54	42
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-181.01%	-	-	-	196.70%	56.31%	-56.42%	-80.39%
Earnings before Interest and Taxes (EBIT)	-50	-76	-169	-205	-93	-121	-227	-177	-150	62	64
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-49	-75	-168	-205	-93	-119	-224	-174	-149	64	67
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-37	-43	-102	-114	59	-45	-182	-93	-64	20	21
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1.03	-11	-28	-57	-182	-222	-198	-231	-276	-241	-220
Increase / (Decrease) in Invested Capital	2.13	-10	-17	-29	-125	-40	24	-33	-45	34	21
Book Value per Share	$12.76	$10.14	$9.34	$2.95	$0.73	($3.45)	($6.77)	($4.39)	($4.00)	($1.97)	($1.26)
Tangible Book Value per Share	$12.75	$10.13	$9.34	$2.95	$0.73	($3.45)	($6.78)	($4.39)	($4.00)	($1.97)	($1.26)
Total Capital	292	231	246	79	20	83	61	-64	-193	-96	-52
Total Debt	4.29	2.73	1.05	0.00	0.00	179	258	260	262	292	249
Total Long-Term Debt	2.69	1.02	0.00	0.00	0.00	179	258	260	262	238	249
Net Debt	-288	-240	-273	-136	-202	-126	-1.05	93	179	148	82
Capital Expenditures (CapEx)	0.30	0.09	0.02	0.15	0.95	0.87	0.00	0.00	0.00	0.32	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.89	-12	-28	-58	-56	-53	-3.71	-12	-37	1.58	-6.09
Debt-free Net Working Capital (DFNWC)	210	200	172	78	146	252	256	154	45	146	162
Net Working Capital (NWC)	209	198	171	78	146	252	256	154	45	92	162
Net Nonoperating Expense (NNE)	15	22	49	59	32	59	110	108	100	106	65
Net Nonoperating Obligations (NNO)	-288	-240	-273	-136	-202	-126	-1.05	93	179	148	82
Total Depreciation and Amortization (D&A)	0.94	1.27	0.59	0.05	0.12	2.19	2.25	2.40	1.45	1.56	3.11
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.26)	($3.33)	($6.98)	($7.54)	($3.59)	$0.00	($9.31)	($3.52)	($2.03)	($0.28)	($0.11)
Adjusted Weighted Average Basic Shares Outstanding	22.54M	22.56M	26.50M	26.82M	27.51M	0.00	28.90M	66.41M	103.11M	187.18M	207.87M
Adjusted Diluted Earnings per Share	($2.26)	($3.33)	($6.98)	($7.54)	($3.59)	$0.00	($9.31)	($3.52)	($2.03)	($0.28)	($0.11)
Adjusted Weighted Average Diluted Shares Outstanding	22.54M	22.56M	26.50M	26.82M	27.51M	0.00	28.90M	66.41M	103.11M	187.18M	207.87M
Adjusted Basic & Diluted Earnings per Share	($2.26)	($3.33)	($6.98)	($7.54)	($3.59)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	22.02M	22.54M	23.93M	26.75M	27.09M	0.00	62.82M	76.57M	185.05M	197.85M	256.81M
Normalized Net Operating Profit after Tax (NOPAT)	-35	-53	-118	-143	-65	-85	-159	-126	-109	38	42
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Esperion Therapeutics' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
DEI Shares Outstanding	94,712,657.00	106,994,269.00	113,717,785.00	113,717,785.00	189,460,293.00	196,224,695.00	-	197,848,886.00	198,199,462.00	201,622,825.00	239,063,437.00
DEI Adjusted Shares Outstanding	94,712,657.00	106,994,269.00	113,717,785.00	113,717,785.00	189,460,293.00	196,224,695.00	-	197,848,886.00	198,199,462.00	201,622,825.00	239,063,437.00
DEI Earnings Per Adjusted Shares Outstanding	-0.53	-0.39	-0.50	0.54	-0.33	-0.15	-	-0.20	-0.06	-0.16	0.26
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-26	-19	-30	72	1.81	-11	-4.42	-15	4.97	-6.97	85
Return On Investment Capital (ROIC_SIMPLE)	-	-	15.33%	-223.99%	-2.21%	10.46%	4.58%	11.61%	-3.67%	4.72%	-162.39%
Earnings before Interest and Taxes (EBIT)	-37	-28	-42	72	2.58	-14	-4.42	-22	7.10	-9.96	85
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-37	-27	-42	73	3.03	-14	-4.22	-21	7.94	-9.09	86
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5.31	20	15	99	23	-23	-39	-26	-45	-19	64
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-250	-264	-276	-259	-271	-252	-241	-248	-221	-240	-220
Increase / (Decrease) in Invested Capital	-31	-40	-45	-27	-21	12	34	11	50	12	21
Book Value per Share	($3.93)	($3.83)	($4.00)	($1.74)	($1.82)	($1.89)	($1.97)	($2.15)	($2.19)	($2.24)	($1.26)
Tangible Book Value per Share	($3.93)	($3.83)	($4.00)	($1.74)	($1.82)	($1.89)	($1.97)	($2.15)	($2.19)	($2.24)	($1.26)
Total Capital	-111	-149	-193	-32	-82	-107	-96	-133	-135	-148	-52
Total Debt	261	261	262	262	262	263	292	293	298	304	249
Total Long-Term Debt	261	261	262	262	262	263	238	238	243	249	249
Net Debt	122	146	179	35	73	118	148	178	212	211	82
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.07	0.08	0.17	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-14	-34	-37	-26	-20	-3.04	1.58	-12	13	-36	-6.09
Debt-free Net Working Capital (DFNWC)	125	81	45	201	170	142	146	102	99	56	162
Net Working Capital (NWC)	125	81	45	201	170	142	92	48	44	1.43	162
Net Nonoperating Expense (NNE)	24	22	27	11	64	18	17	25	18	24	23
Net Nonoperating Obligations (NNO)	122	146	179	35	73	118	148	178	212	211	82
Total Depreciation and Amortization (D&A)	0.40	0.45	0.44	0.44	0.45	0.47	0.20	0.73	0.85	0.87	0.67
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.46)	($0.37)	($0.41)	$0.36	($0.33)	($0.15)	($0.16)	($0.21)	($0.06)	($0.16)	$0.32
Adjusted Weighted Average Basic Shares Outstanding	109.24M	111.87M	103.11M	169.26M	188.79M	194.93M	187.18M	196.13M	197.55M	200.74M	207.87M
Adjusted Diluted Earnings per Share	($0.46)	($0.37)	($0.41)	$0.34	($0.33)	($0.15)	($0.14)	($0.21)	($0.06)	($0.16)	$0.32
Adjusted Weighted Average Diluted Shares Outstanding	109.24M	111.87M	103.11M	189.64M	188.79M	194.93M	187.18M	196.13M	197.55M	200.74M	207.87M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	106.99M	113.72M	185.05M	189.46M	196.22M	197.04M	197.85M	198.20M	201.62M	239.06M	256.81M
Normalized Net Operating Profit after Tax (NOPAT)	-26	-19	-30	51	1.81	-11	-3.09	-15	4.97	-6.97	60
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

Financials Breakdown Chart

Key Financial Trends

Here is a concise, data-driven snapshot of Esperion Therapeutics (ESPR) using the quarterly statements from the last four years. The focus is on profitability, cash flow, and balance-sheet health to help retail investors gauge ongoing risk and potential opportunities.

Q4 2025 net income attributable to common shareholders: $61,831,000 with basic/diluted earnings per share of $0.32, marking a profitable quarter after a stretch of losses.
Q4 2025 operating cash flow turned positive, with net cash from continuing operating activities of $45,243,000 and a net increase in cash of $75,405,000, improving near-term liquidity.
Q4 2025 gross margin around 23%, with gross profit of $39,222,000 on revenue of $168,446,000, signaling a viable gross platform before operating costs.
Q4 2025 financing activity included the issuance of common equity totaling $74,623,000, and net cash from continuing financing activities of $30,162,000, supporting liquidity from equity markets.
Current liquidity is tight but present, with Total Current Assets of $360.464M and Total Current Liabilities of $359.033M in Q3 2025 (roughly a 1.0x current ratio).
Negative shareholder equity persists across the period (Q3 2025 Total Equity of −$451.361M; Q2 2025 −$433.509M; Q1 2025 −$426.211M), signaling solvency risk even with positive quarters.
Leverage remains high; Total Liabilities of about $815.381M in Q3 2025 vs Total Assets of $364.020M, resulting in a large negative equity balance.
Profitability has been volatile; most quarters show net losses (for example Q1 2025 net income −$40.455M, Q2 2025 −$12.725M, Q3 2025 −$31.333M), with Q4 2025 as a rare profitable exception.
Interest expense remains a meaningful drag (Q4 2025: $22.636M; Q3 2025: $22.051M; Q2 2025: $20.486M; Q1 2025: $19.431M) relative to operating results.
Operating cash flow has been negative in several quarters (Q2 2025 CFO −$31.422M; Q3 2025 CFO −$4.286M; Q1 2025 CFO −$22.628M; Q4 2024 CFO −$34.952M), indicating ongoing cash burn despite occasional profitability on paper.

05/07/26 02:20 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Esperion Therapeutics' Financials

When does Esperion Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Esperion Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Esperion Therapeutics' net income changed over the last 10 years?

Esperion Therapeutics' net income were at -$22.68 million at the end of 2025, a 56.2% decrease from 2024, and a 54.4% decrease since 2015. View Esperion Therapeutics' forecast to see where analysts expect Esperion Therapeutics to go next.

What is Esperion Therapeutics' operating income?

Esperion Therapeutics' total operating income in 2025 was $60.27 million, based on the following breakdown:

Total Gross Profit: $273.91 million
Total Operating Expenses: $213.64 million

How has Esperion Therapeutics' revenue changed over the last 10 years?

Over the last 10 years, Esperion Therapeutics' total revenue changed from $0.00 in 2015 to $403.14 million in 2025, a change of 40,313,500,000.0%.

How much debt does Esperion Therapeutics have?

Esperion Therapeutics' total liabilities were at $767.85 million at the end of 2025, a 4.8% increase from 2024, and a 9,136.7% increase since 2015.

How much cash does Esperion Therapeutics have?

In the past 10 years, Esperion Therapeutics' cash and equivalents has ranged from $34.47 million in 2017 to $304.96 million in 2020, and is currently $167.85 million as of their latest financial filing in 2025.

How has Esperion Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Esperion Therapeutics' book value per share changed from 12.76 in 2015 to -1.26 in 2025, a change of -109.9%.

Related Companies

Financial statements for NASDAQ:ESPR last updated on 5/1/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Esperion Therapeutics (ESPR) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Esperion Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Esperion Therapeutics (ESPR) Financials

Annual Income Statements for Esperion Therapeutics

Quarterly Income Statements for Esperion Therapeutics

Annual Cash Flow Statements for Esperion Therapeutics

Quarterly Cash Flow Statements for Esperion Therapeutics

Annual Balance Sheets for Esperion Therapeutics

Quarterly Balance Sheets for Esperion Therapeutics

Annual Metrics And Ratios for Esperion Therapeutics

Quarterly Metrics And Ratios for Esperion Therapeutics

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Esperion Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools